Protective effect of serum maternal antibodies on infants with respiratory syncytial virus infection: a systematic review_Chinese Journal of Evidence-Based Medicine

Authors：

WANG Chenglin ,  TIAN Daiyin

Chongqing Key Laboratory of Pediatrics, Department of Respiratory Disease, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders (Chongqing), Children's Hospital of Chongqing Medical University, Chongqing 400014, P. R. China;

Corresponding author：

TIAN Daiyin, Email: t_dy@163.com

Keywords：

Maternal; Respiratory syncytial virus; Antibody; Infant; Systematic review

DOI：

10.7507/1672-2531.202110015

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the protective effect of serum maternal respiratory syncytial virus (RSV) antibodies on infants with RSV infection. Methods PubMed, EMbase, The Cochrane Library, CBM, CNKI and WanFang Data databases were electronically searched to collect observational studies on the correlation between serum maternal RSV antibodies and infants with RSV infection from inception to July 18, 2021. Two reviewers independently screened literature, extracted data and assessed the risk of bias of the included studies, then, qualitative analysis was performed. Results A total of 19 studies were included, and 60% of those studies suggested that a higher level of maternal antibodies could prevent RSV infection. However, the remaining 40% of them showed that there was no significant difference in the level of RSV maternal antibodies between the infected group and the non-infected group. Further more, in the studies of the correlation between maternal antibody level and disease severity after RSV infection, 55% of those showed that maternal antibody level was negatively correlated with disease severity. Conclusion The protective effect of serum maternal RSV antibodies on infants reported in different studies varies. Whether it can prevent RSV infection and affect the severity of RSV infected children still needs to be explored.

Citation： WANG Chenglin, TIAN Daiyin. Protective effect of serum maternal antibodies on infants with respiratory syncytial virus infection: a systematic review. Chinese Journal of Evidence-Based Medicine, 2022, 22(3): 338-344. doi: 10.7507/1672-2531.202110015 Copy

1.	Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med, 2009, 360(6): 588-598.
2.	Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet, 2010, 375(9725): 1545-1555.
3.	Simões EA, Mutyara K, Soh S, et al. The epidemiology of respiratory syncytial virus lower respiratory tract infections in children less than 5 years of age in Indonesia. Pediatr Infect Dis J, 2011, 30(9): 778-784.
4.	Chatterjee A, Mavunda K, Krilov LR. Current state of respiratory syncytial virus disease and management. Infect Dis Ther, 2021, 10(Suppl 1): 5-16.
5.	Graham BS, Modjarrad K, McLellan JS. Novel antigens for RSV vaccines. Curr Opin Immunol, 2015, 35: 30-38.
6.	Graham BS. Vaccine development for respiratory syncytial virus. Curr Opin Virol, 2017, 23: 107-112.
7.	Guvenel AK, Chiu C, Openshaw PJ. Current concepts and progress in RSV vaccine development. Expert Rev Vaccines, 2014, 13(3): 333-344.
8.	Giles ML, Krishnaswamy S, Wallace EM. Maternal immunisation: What have been the gains? Where are the gaps? What does the future hold? F1000Res, 2018, 7: 1733.
9.	Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med, 2008, 359(15): 1555-1564.
10.	Amirthalingam G, Andrews N, Campbell H, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet, 2014, 384(9953): 1521-1528.
11.	Buchwald AG, Graham BS, Traore A, et al. Respiratory syncytial virus (RSV) neutralizing antibodies at birth predict protection from RSV illness in infants in the first 3 months of life. Clin Infect Dis, 2021, 73(11): e4421-e4427.
12.	Eick A, Karron R, Shaw J, et al. The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease. Pediatr Infect Dis J, 2008, 27(3): 207-212.
13.	Kasel JA, Walsh EE, Frank AL, et al. Relation of serum antibody to glycoproteins of respiratory syncytial virus with immunity to infection in children. Viral Immunol, 1987-1988, 1(3): 199-205.
14.	Ogilvie MM, Vathenen AS, Radford M, et al. Maternal antibody and respiratory syncytial virus infection in infancy. J Med Virol, 1981, 7(4): 263-271.
15.	Chu HY, Tielsch J, Katz J, et al. Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural Nepal. J Clin Virol, 2017, 95: 90-95.
16.	Nyiro JU, Sande CJ, Mutunga M, et al. Absence of association between cord specific antibody levels and severe respiratory syncytial virus (RSV) disease in early infants: a case control study from coastal Kenya. PLoS One, 2016, 11(11): e0166706.
17.	Bulkow LR, Singleton RJ, Karron RA, et al. Risk factors for severe respiratory syncytial virus infection among Alaska native children. Pediatrics, 2002, 109(2): 210-216.
18.	Holberg CJ, Wright AL, Martinez FD, et al. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am J Epidemiol, 1991, 133(11): 1135-1151.
19.	Capella C, Chaiwatpongsakorn S, Gorrell E, et al. Prefusion F, postfusion F, G antibodies, and disease severity in infants and young children with acute respiratory syncytial virus infection. J Infect Dis, 2017, 216(11): 1398-1406.
20.	Roca A, Abacassamo F, Loscertales MP, et al. Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique. J Med Virol, 2002, 67(4): 616-623.
21.	Koivisto K, Nieminen T, Mejias A, et al. RSV specific antibodies in pregnant women and subsequent risk of RSV hospitalization in young infants. J Infect Dis, 2021: jiab315.
22.	van Erp EA, Lakerveld AJ, de Graaf E, et al. Natural killer cell activation by respiratory syncytial virus-specific antibodies is decreased in infants with severe respiratory infections and correlates with Fc-glycosylation. Clin Transl Immunology, 2020, 9(2): e1112.
23.	Jans J, Wicht O, Widjaja I, et al. Characteristics of RSV-specific maternal antibodies in plasma of hospitalized, acute RSV patients under three months of age. PLoS One, 2017, 12(1): e0170877.
24.	Stensballe LG, Ravn H, Kristensen K, et al. Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. J Allergy Clin Immunol, 2009, 123(2): 398-403.
25.	Glezen WP, Paredes A, Allison JE, et al. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr, 1981, 98(5): 708-715.
26.	Taleb SA, Al-Ansari K, Nasrallah GK, et al. Level of maternal respiratory syncytial virus (RSV) F antibodies in hospitalized children and correlates of protection. Int J Infect Dis, 2021, 109: 56-62.
27.	Walsh EE, Wang L, Falsey AR, et al. Virus-specific antibody, viral load, and disease severity in respiratory syncytial virus infection. J Infect Dis, 2018, 218(2): 208-217.
28.	Toms GL, Webb MS, Milner PD, et al. IgG and IgM antibodies to viral glycoproteins in respiratory syncytial virus infections of graded severity. Arch Dis Child, 1989, 64(12): 1661-1665.
29.	Lamprecht CL, Krause HE, Mufson MA. Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis, 1976, 134(3): 211-217.
30.	WHO. Revised WHO classification and treatment of childhood pneumonia at health facilities. Geneva:WHO, 2014: 6-14.
31.	McConnochie KM, Hall CB, Walsh EE, et al. Variation in severity of respiratory syncytial virus infections with subtype. J Pediatr, 1990, 117(1 Pt 1): 52-62.
32.	Gove S. Integrated management of childhood illness by outpatient health workers: technical basis and overview. The WHO working group on guidelines for integrated management of the sick child. Bull World Health Organ, 1997, 75(Suppl 1): 7.
33.	Mejias A, Dimo B, Suarez NM, et al. Whole blood gene expression profiles to assess pathogenesis and disease severity in infants with respiratory syncytial virus infection. PLoS Med, 2013, 10(11): e1001549.
34.	Wang EE, Milner RA, Navas L, et al. Observer agreement for respiratory signs and oximetry in infants hospitalized with lower respiratory infections. Am Rev Respir Dis, 1992, 145(1): 106-109.
35.	Caserta MT, Qiu X, Tesini B, et al. Development of a global respiratory severity score for respiratory syncytial virus infection in infants. J Infect Dis, 2017, 215(5): 750-756.
36.	郝焕, 聂建辉, 王玉琳, 等. 呼吸道合胞病毒融合蛋白变异及其对抗体和药物效果的影响. 中国病毒病杂志, 2021, 11(1): 63-69.
37.	Joyce MG, Zhang B, Ou L, et al. Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nat Struct Mol Biol, 2016, 23(9): 811-820.

1. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med, 2009, 360(6): 588-598.
2. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet, 2010, 375(9725): 1545-1555.
3. Simões EA, Mutyara K, Soh S, et al. The epidemiology of respiratory syncytial virus lower respiratory tract infections in children less than 5 years of age in Indonesia. Pediatr Infect Dis J, 2011, 30(9): 778-784.
4. Chatterjee A, Mavunda K, Krilov LR. Current state of respiratory syncytial virus disease and management. Infect Dis Ther, 2021, 10(Suppl 1): 5-16.
5. Graham BS, Modjarrad K, McLellan JS. Novel antigens for RSV vaccines. Curr Opin Immunol, 2015, 35: 30-38.
6. Graham BS. Vaccine development for respiratory syncytial virus. Curr Opin Virol, 2017, 23: 107-112.
7. Guvenel AK, Chiu C, Openshaw PJ. Current concepts and progress in RSV vaccine development. Expert Rev Vaccines, 2014, 13(3): 333-344.
8. Giles ML, Krishnaswamy S, Wallace EM. Maternal immunisation: What have been the gains? Where are the gaps? What does the future hold? F1000Res, 2018, 7: 1733.
9. Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med, 2008, 359(15): 1555-1564.
10. Amirthalingam G, Andrews N, Campbell H, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet, 2014, 384(9953): 1521-1528.
11. Buchwald AG, Graham BS, Traore A, et al. Respiratory syncytial virus (RSV) neutralizing antibodies at birth predict protection from RSV illness in infants in the first 3 months of life. Clin Infect Dis, 2021, 73(11): e4421-e4427.
12. Eick A, Karron R, Shaw J, et al. The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease. Pediatr Infect Dis J, 2008, 27(3): 207-212.
13. Kasel JA, Walsh EE, Frank AL, et al. Relation of serum antibody to glycoproteins of respiratory syncytial virus with immunity to infection in children. Viral Immunol, 1987-1988, 1(3): 199-205.
14. Ogilvie MM, Vathenen AS, Radford M, et al. Maternal antibody and respiratory syncytial virus infection in infancy. J Med Virol, 1981, 7(4): 263-271.
15. Chu HY, Tielsch J, Katz J, et al. Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural Nepal. J Clin Virol, 2017, 95: 90-95.
16. Nyiro JU, Sande CJ, Mutunga M, et al. Absence of association between cord specific antibody levels and severe respiratory syncytial virus (RSV) disease in early infants: a case control study from coastal Kenya. PLoS One, 2016, 11(11): e0166706.
17. Bulkow LR, Singleton RJ, Karron RA, et al. Risk factors for severe respiratory syncytial virus infection among Alaska native children. Pediatrics, 2002, 109(2): 210-216.
18. Holberg CJ, Wright AL, Martinez FD, et al. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am J Epidemiol, 1991, 133(11): 1135-1151.
19. Capella C, Chaiwatpongsakorn S, Gorrell E, et al. Prefusion F, postfusion F, G antibodies, and disease severity in infants and young children with acute respiratory syncytial virus infection. J Infect Dis, 2017, 216(11): 1398-1406.
20. Roca A, Abacassamo F, Loscertales MP, et al. Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique. J Med Virol, 2002, 67(4): 616-623.
21. Koivisto K, Nieminen T, Mejias A, et al. RSV specific antibodies in pregnant women and subsequent risk of RSV hospitalization in young infants. J Infect Dis, 2021: jiab315.
22. van Erp EA, Lakerveld AJ, de Graaf E, et al. Natural killer cell activation by respiratory syncytial virus-specific antibodies is decreased in infants with severe respiratory infections and correlates with Fc-glycosylation. Clin Transl Immunology, 2020, 9(2): e1112.
23. Jans J, Wicht O, Widjaja I, et al. Characteristics of RSV-specific maternal antibodies in plasma of hospitalized, acute RSV patients under three months of age. PLoS One, 2017, 12(1): e0170877.
24. Stensballe LG, Ravn H, Kristensen K, et al. Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. J Allergy Clin Immunol, 2009, 123(2): 398-403.
25. Glezen WP, Paredes A, Allison JE, et al. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr, 1981, 98(5): 708-715.
26. Taleb SA, Al-Ansari K, Nasrallah GK, et al. Level of maternal respiratory syncytial virus (RSV) F antibodies in hospitalized children and correlates of protection. Int J Infect Dis, 2021, 109: 56-62.
27. Walsh EE, Wang L, Falsey AR, et al. Virus-specific antibody, viral load, and disease severity in respiratory syncytial virus infection. J Infect Dis, 2018, 218(2): 208-217.
28. Toms GL, Webb MS, Milner PD, et al. IgG and IgM antibodies to viral glycoproteins in respiratory syncytial virus infections of graded severity. Arch Dis Child, 1989, 64(12): 1661-1665.
29. Lamprecht CL, Krause HE, Mufson MA. Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis, 1976, 134(3): 211-217.
30. WHO. Revised WHO classification and treatment of childhood pneumonia at health facilities. Geneva:WHO, 2014: 6-14.
31. McConnochie KM, Hall CB, Walsh EE, et al. Variation in severity of respiratory syncytial virus infections with subtype. J Pediatr, 1990, 117(1 Pt 1): 52-62.
32. Gove S. Integrated management of childhood illness by outpatient health workers: technical basis and overview. The WHO working group on guidelines for integrated management of the sick child. Bull World Health Organ, 1997, 75(Suppl 1): 7.
33. Mejias A, Dimo B, Suarez NM, et al. Whole blood gene expression profiles to assess pathogenesis and disease severity in infants with respiratory syncytial virus infection. PLoS Med, 2013, 10(11): e1001549.
34. Wang EE, Milner RA, Navas L, et al. Observer agreement for respiratory signs and oximetry in infants hospitalized with lower respiratory infections. Am Rev Respir Dis, 1992, 145(1): 106-109.
35. Caserta MT, Qiu X, Tesini B, et al. Development of a global respiratory severity score for respiratory syncytial virus infection in infants. J Infect Dis, 2017, 215(5): 750-756.
36. 郝焕, 聂建辉, 王玉琳, 等. 呼吸道合胞病毒融合蛋白变异及其对抗体和药物效果的影响. 中国病毒病杂志, 2021, 11(1): 63-69.
37. Joyce MG, Zhang B, Ou L, et al. Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nat Struct Mol Biol, 2016, 23(9): 811-820.

Chinese Journal of Evidence-Based Medicine

Protective effect of serum maternal antibodies on infants with respiratory syncytial virus infection: a systematic review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content